Comparison
Modafinil vs Yohimbine
Modafinil
A eugeroic — a wakefulness-promoting compound — originally developed for narcolepsy. The most-studied prescription cognitive enhancer outside of ADHD treatment. Produces 12–15 hour windows of sustained alertness without the euphoria, abuse potential, or cardiovascular load of amphetamines. Prescription-only in nearly every jurisdiction.
Yohimbine
Alkaloid from Pausinystalia yohimbe bark. Alpha-2 adrenergic antagonist. Increases norepinephrine. Used for fat loss, libido, and acute focus.
| Field | Modafinil | Yohimbine |
|---|---|---|
| Category | stimulant | stimulant |
| Dose range | 100–200mg | 2.5–10mg |
| Half-life | 14h | 0.5h |
| Onset | 45min | 20min |
| Evidence | EVIDENCEA | EVIDENCEB |
| Safety | ●●●○○ | ●●○○○ |
| Legal (US) | USSchedule IV | USOTC |
| PubMed refs | 3200 | 720 |
The comparison in plain English
Auto-generated from dataModafinil and Yohimbine are both in the stimulant category respectively. Modafinil A eugeroic — a wakefulness-promoting compound — originally developed for narcolepsy. Yohimbine Alkaloid from Pausinystalia yohimbe bark.
Bottom line
Modafinil (evidence A, safety 3/5) has a weaker evidence base than Yohimbine (evidence B, safety 2/5). Modafinil has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Modafinil if
Modafinil is the better fit when your goal aligns with its mechanism (Inhibits dopamine reuptake via the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex) and the dose range (100–200mg) suits your protocol. Half-life is 14h.
Choose Yohimbine if
Yohimbine is the better fit when your goal aligns with its mechanism (Alpha-2 adrenergic receptor antagonist) and the dose range (2.5–10mg) suits your protocol. Half-life is 0.5h.